⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643368 | 0.82 | — | — | |
| SCHEMBL27829000 | 0.80 | — | — | |
| SCHEMBL24690339 | 0.78 | — | — | |
| SCHEMBL3313843 | 0.78 | — | — | |
| Phosphine SCHEMBL27533497 | 0.78 | SSTR4 (0.47) | — | |
| SCHEMBL24576137 | 0.78 | — | — | |
| SCHEMBL27487832 | 0.78 | — | — | |
| SCHEMBL37447 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL20424376 | 0.77 | SSTR4 (0.46) | — | |
| SCHEMBL27709202 | 0.77 | SSTR4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-08-19 | — | — | US | disclosed |
| CN-112961149-A | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| EP-3180335-B1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-107074841-B | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10556893-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10414760-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180334455-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
| US-20060019957-A1 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060009645-A1 | Naphthylene derivatives as cytochrome P450 inhibitors | OSI PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005007631-A1 | NAPHTHYLENE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | disclosed |
| CN-1441790-A | Enhanced propertied pharmaceuticals | ROHM & HAAS (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | disclosed |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | MULVIHILL MARK JOSEPH (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |